Genitourinary Cancers | Specialty

Expert Highlights Potential of Erdafitinib in Urothelial Carcinoma

August 10th 2018

Arlene O. Siefker-Radtke, MD, discusses the promise of erdafitinib in patients with urothelial carcinoma.

Dr. Gupta on Genomic Characterization of MIBC Histology to Predict Response

August 9th 2018

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses genomic characterization of muscle invasive bladder cancer histology to predict therapy response.

Enfortumab Vedotin Emerging as Post-Immunotherapy Option in Bladder Cancer

August 9th 2018

Jonathan E. Rosenberg, MD, discusses the promise of enfortumab vedotin in patients with bladder cancer who previously received a checkpoint inhibitor, and reflects on the rapid pace of change in the urothelial cancer landscape.

Sznol Reflects on Immunotherapy Advances in mRCC

August 9th 2018

Mario Sznol, MD, discusses the latest developments with immunotherapy in metastatic renal cell carcinoma.

Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma

August 8th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.

Dr. Drake on the Role of Cytoreductive Nephrectomy in RCC

August 7th 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.

Rethinking the Prostate Cancer Paradigm in the Urology Community

August 4th 2018

Raoul S. Concepcion, MD, FACS, discusses how to sort through the massive amount of data in the urology space, gain a basic understanding of its significance, and determine its clinical utility.

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

August 3rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.

Dr. Agarwal on Emerging Immunotherapeutic Combinations in Kidney Cancer

August 3rd 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging immunotherapeutic combinations in kidney cancer.

Surgical Challenges and Opportunities in Treating Penile Cancer

August 3rd 2018

Kevin R. Loughlin, MD, MBA, discusses the diagnosis, staging, and management of penile cancer.

Dr. Siefker-Radtke on the Treatment of FGFR-Altered Bladder Cancer

August 3rd 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with bladder cancer who have fibroblast growth factor receptor (FGFR)-altered tumors.

Early Pembrolizumab/Bevacizumab Study Shows Promise in RCC

August 2nd 2018

Shilpa Gupta, MD, discusses the tolerability and safety of pembrolizumab and bevacizumab in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.

Dr. Drake Discusses the Results of the CARMENA Study in RCC

August 2nd 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.

Practice in South Texas Offers Vertically Integrated Cancer Care

July 30th 2018

Providing comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.

Future Directions for Research in mRCC

July 30th 2018

PD-L1 Testing in mRCC

July 30th 2018

Novel Combination Therapies Under Investigation in mRCC

July 30th 2018

Emerging TKI/I-O Options in mRCC

July 30th 2018

TKI/I-O Therapy in mRCC

July 30th 2018

Therapeutic Sequencing in mRCC

July 30th 2018